On May 3, 2022 Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, reported that data from its KRAS program will be presented in an oral presentation at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) (Press release, Affini-T Therapeutics, MAY 3, 2022, View Source [SID1234613430]). The data from Affini-T Therapeutics will be delivered by Tijana Martinov, Ph.D. from the Greenberg Lab at Fred Hutchinson Cancer Center .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"KRAS mutations are the most prevalent oncogenic drivers in solid tumor cancers with G12V and G12D variants representing the most common substitutions within this oncogene," said Loïc Vincent, Ph.D., Chief Scientific Officer, Affini-T Therapeutics. "We are excited that our TCR-engineered T cell therapies, designed to orchestrate a coordinated CD4 and CD8 T cell response while targeting these common mutant variants of KRAS, show promising preclinical safety and efficacy profiles that support clinical development for solid tumor patients with KRAS mutations who have high unmet medical needs."

Presentation details are as follows:

Title: Preclinical Development of Safe and Effective T Cell Receptors Specific for Mutant KRAS G12V and G12D Peptides
Presenting Author: Tijana Martinov, Ph.D.
Abstract Number: 103
Session Title: Cell-Based Cancer Immunotherapies I
Date & Time: Monday, May 16, 2022 at 4:45pm – 5:00pm ET